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Abstract
Background: To better search for potential markers for hepatocellular carcinoma (HCC) invasion and metastasis,
proteomic approach was applied to identify potential metastasis biomarkers associated with HCC.
Methods: Membrane proteins were extracted from MHCC97L and HCCLM9 cells, with a similar genetic
background and remarkably different metastasis potential, and compared by SDS-PAGE and identified by ESI-MS/
MS. The results were further validated by western blot analysis, immunohistochemistry (IHC) of tumor tissues from
HCCLM9- and MHCC97L-nude mice, and clinical specimens.
Results: Membrane proteins were extracted from MHCC97L and HCCLM9 cell and compared by SDS-PAGE
analyses. A total of 14 differentially expressed proteins were identified by ESI-MS/MS. Coronin-1C, a promising
candidate, was found to be overexpressed in HCCLM9 cells as compared with MHCC97L cells, and validated by
western blot and IHC from both nude mice tumor tissues and clinical specimens. Coronin-1C level showed an
abrupt upsurge when pulmonary metastasis occurred. Increasing coronin-1C expression was found in liver cancer
tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis. IHC study on human HCC specimens
revealed that more patients in the higher coronin-1C group had overt larger tumor and more advanced stage.
Conclusions: Coronin-1C could be a candidate biomarker to predict HCC invasive behavior.
Background
Hepatocellular carcinoma (HCC), accounting for an esti-
mated 600,000 deaths annually, is the third leading
cause of cancer-related mortality worldwide [1]. Most
cases occur in Asia and sub-Saharan Africa [2,3], how-
ever, the incidence is also expected to double over the
next 10 to 20 years in the West, possibly due to the
increased HCV infection [4]. While curative therapies
are possible if the lesion remains early and localized,
almost 70% of resected cases recurred within 5 years [5].
Although impressive progression has been made in pro-
viding an increasingly comprehensive portrayal of HCC
[3,6,7], biomarkers that indicate the risk of invasion and
metastatic potential of HCC and can be widely used in
clinical settings are not currently available [8,9].
For a better insight into the characteristic of HCC
metastasis, the stepwise metastatic human HCC cells
MHCC97L and HCCLM9, with low and high metastatic
potentials, were established via repeated in vivo selection
and characterized by a similar genetic background but
with significant differences in spontaneous metastasis
behavior [10-12], providing appropriate model systems
for comparative study on the molecular events corre-
lated with HCC metastasis [13-15].
Plasma membrane, the structure surrounding all living
cells and acting as the primary interface between the
cellular contents and the extracellular environment,
plays crucial roles in cell functions. Membrane proteins
and other components maintain cell structure, motility
and recognition [16] involved in receptor-binding and
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cell-cell and cell-matrix interactions, and the organiza-
tion of the cytoskeleton [16-18]. The composition and
characteristics of membrane proteins of tumor cells are
modified during malignant transformation and make
them likely candidates for cancer biomarkers [19]. Com-
parative proteomics with the recent advances are pro-
mising tools for discovering novel invasive and
metastasis-associated candidate biomarkers of HCC.
The current work was to identify potential membrane
proteins related to HCC invasive progression, using
human HCC cells with different metastasis potentials,
by proteomics analysis, experimental animal studies and
clinical validation. To gain insights into potential candi-
date biomarkers contributing to invasion and metastasis,
two well defined and unique HCC cells with multiple
progressive and metastatic potentials, HCCLM9 cell
with a highly lung metastasis rate 100%, and MHCC97L
cell with a low lung metastasis rate 0% [12-14], were
selected as our study models.
Methods
Cell lines and cell culture
The two cloned cell lines, MHCC97L and HCCLM9, are
derived from the same host cell line MHCC97, in a pro-
cess of cloning culture and 9 successive in vivo pulmon-
ary metastases selection, as described previously [1,2].
These cells are cultured at 37°C in 5% CO2/95% air and
RPMI 1640 (Sigma, USA) supplemented with 10% fetal
bovine serum (Amresco, USA). Cells are grown to 80%
confluence and passaged.
Membrane proteins extraction
Membrane proteins from cultured cells were extracted
using ProteoExtract® subcellular proteome extraction kit
(Cat. No. 539790, Merck, Germany) according to the
protocol. All samples were stored at -80°C
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
After the BCA assay (Pierce, Rockford, IL) to quantify
protein concentration, equal amounts of protein were
loaded onto 12% gels (Invitrogen, Carlsbad, CA) and
separated by SDS-PAGE. The gels were soaked in Coo-
massie brilliant blue dye overnight and excess stain was
then eluted with a solvent (destaining).
In-gel proteolytic digestion
The differential proteins band were excised manually
from Coomassie brilliant blue stained gel with a disposa-
ble pipette, cut into small pieces, and transferred into
0.5 ml Eppendorf tubes. The gel pieces were destained
by adding 60 μl acetonitrile/200 mM NH4HCO3 (1:1),
vortexed 5 min, and centrifuged at 12,000 × g for 5 min
and then the supernatant removed. This step was
repeated until the gel pieces were completely destained.
60 μl acetonitrile were added, vortexed for 5 min, and
centrifuged at 12,000 × g for 5 min and then the super-
natant removed, this was repeated twice until the gel
pieces were completely white. The gel pieces were dried,
rehydrated, and incubated in 18 μl ice-cold trypsin solu-
tion (12.5 ng/mL in 0.1 M NH4HCO3)a t4 ° Cf o r
20 min. The supernatant was removed and pipetted in
15 μl of the previous buffer without trypsin to maintain
proteolytic digestion for 12 h at 37°C in a wet environ-
ment. We added 60 μl extract solution (5% formic acid
in 50% acetonitrile) then sonicated the extract solution
for 5 min. Peptides were collected in supernatant.
Protein identification by ESI-MS/MS
ESI-MS/MS was conducted on a capillary system
equipped with the Aksigent autosapmler(NanoLC-2D
system, US.). A reverse-phase column (C18, OD = 360
μm, ID = 4.6 μm) was used to separate. The compart-
ment of the autosampler was set at 10°C throughout the
analysis. The mobile phase consisted of two components,
with component (A) being 0.1% acetic acid and compo-
nent (B) being 60% acetonitrile and 0.1% acetic acid. The
solvent gradient was started from 5% B and held for
5 min, then programmed to 60% B in 40 min, and held
for another 5 min, all at a flow rate of 300 L/min. MS-
MS analysis were conducted on a Q-tof tandem mass
spectrometer (Applied Biosystems, CA, USA). Positive
ion mode ESI-MS was used for the analysis, with the
TurboIonspray parameters optimized as follows: ionspray
voltage (IS) 2200 V, declustering potential 60 V. The
mass range chosen ranged from m/z 400 to m/z 1600.
The ion source gas I (GSI), gas II (GSII), curtain gas
(CUR), and the temperature of GSII were set at 40, 5, 30
and 175°C, respectively.
Western blotting
After the BCA assay (Pierce, Rockford, IL) was used to
quantify protein concentration, equal amounts of pro-
tein were loaded onto 12% gels (Invitrogen, Carlsbad,
CA), separated by SDS-PAGE, and transferred to PVDF
membranes (Immobilon 0.2 μm, Millipore, CA), which
were then immersed in a blocking solution containing
5% skimmed milk and 0.1% Tween for 20 min. After-
wards, the membranes were washed and incubated with
rabbit anti-coronin-1C (1:2000; Protein Tech Group,
CA) or goat anti-integrin alpha 3 (ITGA3) (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
4°C and then with goat anti-rabbit and rabbit anti-goat
secondary antibody (1:3000; Protein Tech Group, CA)
for 2 h at room temperature. Enhanced chemilumines-
cence (ECL; Amersham Biosciences, Piscataway, NJ) was
used to visualize the immunoreactive bands. All bands
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bioimaging systems (Synoptics Ltd, UK).
Animals and nude mice model of spontaneous pulmonary
metastasis
Male athymic BALB/c nu/nu mice, 4 wks old, were
obtained from Experimental Animal Institute of Hubei
Center for Disease Control and Prevention and main-
tained in specific pathogen-free (SPF) condition at the
Animal Experiment Center of Wuhan University. The
facilities and the protocol of this experiment were consis-
tent with the regulations on animal use for biomedical
experiments issued by the Ministry of Science and Tech-
nology of China, and approved by the Animal Care Com-
mittee of Wuhan University. Both MHCC97L- and
HCCLM9- nude mice were produced as described pre-
viously [12]. All mice were sacrificed under deep anesthe-
sia by peritoneal injection of 3% phentobarbital chloride
in approximately 6 wks after surgery. Liver samples were
collected and stored at -80°C refrigerator. The lungs were
f i x e di n1 0 %n e u t r a lf o r m a l i ns o l u t i o na n dp r o c e s s e df o r
conventional pathological study to validate the model.
Immunohistochemical staining of coronin-1C
Immunohistochemistry (IHC) was performed on 4-5 μm
thick paraffin sections. Sections were deparaffinized and
rehydrated with graded ethanols. For immunostaining,
VECTORSTAIN ABC kit (Vector Lab, CA) was used
according to the manufacturer’s instructions. Primary
antibodies used were rabbit anti-coronin-1C (Protein
Tech Group, CA).
Tumor development of spontaneous pulmonary
metastasis in nude mice model of HCC
Highly spontaneous metastatic nude mice model
(HCCLM9 group) of human HCC was used to study the
relationship between coronin-1C levels and tumor pro-
gressive and metastasis. Twenty-four nude mice
(HCCLM9) were produced as described previously. The
mice were randomly divided into three groups of eight
mice in each group. At the end of the fourth, fifth and
sixth wk, one group of was sacrificed. Liver cancer and
lung samples were stored -80°C refrigerator.
Clinical validation
HCC specimens from 115 patients including 96(83.5%)
males and 19(16.5%) females with mean age (M ± SD)
of 47.9 ± 12.4 years (range 18-78) were obtained from
Fanpu Biotech, Inc. All tumors were fixed with formalin
and embedded with paraffin. Ten high power field of
each tissue section were selected randomly and observed
double blind by two investigators. The staining score of
each section were calculated by staining intensity and
positive rate of cancer cells. Staining intensity: the score
of no staining, weakly staining and strong staining is 0,
1 and 2 respectively. Positive rate of cancer cells: 0-20%
was recorded as 0; 20-50% was recorded as 1; >50% was
recorded as 2. The sum of scores was computed as the
score of staining intensity added the score of the posi-
tive rate of cancer cells. Then it was graded according
the sum of scores: 0 (-); 1-2 (+); 3-4 (++).
Statistical analysis
All the experiment data were integrated into a compre-
hensive data set. Numerical data were recorded directly.
Chi-square test and Fisher’s exact test were used to
compare the clinicopathologic parameters among
patients with different level of coronin-1C expression.
Statistical analysis was performed on SPSS software ver-
sion 13.0 (SPSS Inc. Chicago, IL), and P < 0.05 was con-
sidered as statistically significant.
Results
Differential expression of coronin-1C between HCCLM9
and MHCC97L cell strains as identified by ESI-MS/MS
Membrane proteins were extracted from MHCC97L and
HCCLM9 HCC cells and compared by SDS-PAGE ana-
lyses [Fig. 1A]. The differential and interesting protein
bands were excised and analyzed by ESI-MS/MS. A
total of 14 proteins were identified by ESI-MS/MS
among the differential bands [Table 1, Fig. 1A]. Coro-
nin-1C, a promising candidate, was identified with high
confidence [Fig. 1B].
Verification of coronin-1C differential expression by
western blot
Western blotting was conduced to further validate coro-
nin-1C, as it has the advantage of enhanced sensitivity
and specificity. ITGA3, a typical membrane protein, was
used as a control. As our data show that coronin-1C
from membrane proteins of HCCLM9 cells rose signifi-
cantly as compared with MHCC97L [Fig. 2].
Immunohistochemical staining (IHC) of coronin-1C in
HCCLM9- and MHCC97L- nude mice model of HCC
We had explored the relationship between coronin-1C
expression and tumor spontaneous pulmonary metasta-
sis in the nude mice model of HCC by IHC. Elevated
coronin-1C expression was observed in liver cancer tis-
sues of HCCLM9-nude mice [Fig. 3A, 3B], with highly
lung metastasis rate 100% [Fig. 3C], compared with
MHCC97L-nude mice, with no lung metastasis.
Tumor development of spontaneous pulmonary
metastasis in nude mice model of human HCC and
tissues cronin-1C level
We had investigated the relationship between cronin-1C
expression and tumor spontaneous pulmonary
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became accelerated from the third week on. No nude
mouse had spontaneous pulmonary metastasis at the
end of the fourth wk. On the fifth wk the mice showed
signs of distress and histopathological study of the lungs
showed conspicuous metastases. Simultaneously tumor
tissues coronin-1C level rose remarkably, and represen-
tative images are presented in Fig. 4.
Coronin-1C expression in HCC specimens
We further investigated Coronin-1C expression in clini-
cal HCC tissues using IHC analysis. Representative
images are presented in Fig. 5. Coronin-1C was strongly
stained (score ++) in 41 cases of the 115 samples
(35.7%), weakly stained (score +) in 53 cases (46.1%)
and not stained (score-) in 21 cases (18.3%). Significant
differences in coronin-1C expression were observed
among HCC specimens of different clinical stages. But
there was no significant correlation between Coronin-
1C expression with age and sex [Table 2].
Discussion
Metastasis is a major cause of high mortality in HCC
patients after surgical resection. To tackle the challenge,
more prognostic biomarkers that could predict the pro-
gression and metastasis of cancer should be explored.
Efforts have been made to find molecules of HCC pro-
gression and metastasis, including Alpha-fetoprotein
(AFP) [20], Alpha-fetoprotein-L3 (AFPR-L3) [21], des-g-
carboxy-prothrombin (DCP) [22], a-Fucosidase [23], Gly-
pican-3 [24], transforming growth factor-b1 (TGFb) [25],
insulin-like growth factor-II (IGF-II) [26], insulin-like
Figure 1 Coronin-1C was identified as differentially expressed protein between HCCLM9 and MHCC97L cells. (A) Membrane proteins
were extracted from MHCC97L and HCCLM9 cells and compared by SDS-PAGE analyses. (B) The differential and interesting protein bands were
excised and analyzed by ESI-MS/MS. One of MS/MS maps for Coronin-1C identification and the sequence of precursor were analyzed by MS/MS
to be R.AIFLADGNVFTTGFSR.M.
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Confirmation of coronin-1C expression by western blot analysis between HCCLM9 and MHCC97L cells. ITGA3, a typical membrane protein, was
used as a control. (B) Densiometric scan of immunoblots shown in A.
Table 1 Differentially expressed proteins between HCCLM9- and MHCC97L -cell identified by ESI-MS/MS
Protein Name Swiss-Prot Accession Summary Score
a
Protein fto Q9C0B1 84
UTP–glucose-1-phosphate uridylyltransferase Q16851 78
Importin subunit alpha-1 P52294 71
1-acylglycerophosphocholine O-acyltransferase 1 Q8NF37 63
Tryptophanyl-tRNA synthetase, cytoplasmic P23381 60
Proto-oncogene tyrosine-protein kinase Fyn P06241 56
ERO1-like protein alpha Q96HE7 55
EH domain-containing protein 1 Q9H4M9 54
RuvB-like 2 Q9Y230 53
Glycylpeptide N-tetradecanoyltransferase 1 P30419 49
U4/U6 small nuclear ribonucleoprotein Prp31 Q8WWY3 46
Copine-1 Q99829 45
Adenylyl cyclase-associated protein 1 Q01518 44
Coronin-1C Q9ULV4 44
a Individual ions scores > 35 indicate identity or extensive homology, P < 0.05.
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nude mice model of HCC. Elevated coronin-1C expression was
observed in liver cancer tissues of HCCLM9-nude mice. (A) Coronin-
1C expression in tumor tissues of MHCC97L nude mice model of
HCC by IHC. ×400; (B) Coronin-1C expression in tumor tissues of
HCCLM9 nude mice model of HCC by IHC. ×400; (C) Spontaneous
lung metastases occurred in HCCLM9- nude mice.
Figure 4 Tissues coronin-1C level and development of
spontaneous pulmonary metastasis in nude mice model of HCC.
Tumor tissues coronin-1C level rose remarkably at the end of the
fifth wk. (A) Coronin-1C expression at the end of the fourth wk by
IHC, ×400; (B) Coronin-1C expression at the end of the fifth wk by
IHC, ×400;
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cervical cancer oncogene (HCCR) [28], Golgi protein 73
(GP73) [29], hepatocyte growth factor (HGF) [30], KL-6
[31], vascular endothelial growth factor (VEGF) [32], and
tumor-associated antigens (TAAs) [33]. However, HCC
metastasis-associated indicators for clinical utility are still
lacking. Advances have been made in genomics and pro-
teomics to discover novel biomarkers for predication and
diagnosis of cancer invasion and metastasis [34-37].
Our previous work applied two-dimensional gel elec-
trophoresis (2-DE), matrix assisted laser desorption ioni-
zation/time of flight MS (MAIDLI-TOF-MS) and MS/
MS to study the protemics profile differences between
MHCC97L and MHCC97H [15]. Cytokeratin 19 was
found to be correlated to HCC metastasis [15]. How-
ever, membrane proteins could be lost because of 2-DE
innate limitations. The current study focused on mem-
brane proteins, extracted from MHCC97L and
HCCLM9 cells and compared by SDS-PAGE analyses.
Among the differentially expressed candidate proteins,
coronin-1C was found overexpressed in HCCLM9 cell
as compared with MHCC97L cells, and further validated
by western blot, animal model studies and clinical vali-
dations, suggesting that coronin-1C may be related to
the metastasis phenotype of HCC.
Figure 5 The expression of coronin-1C human HCC specimens.
Significant differences in coronin-1C expression were observed
among HCC specimens of different clinical stages. (A) Score-, ×400;
(B) Score +, ×400; (C) Score ++, ×400.
Table 2 Correlation between tumor tissue coronin-1C
































Female 5 (26.3) 7 (36.8) 7 (36.8)
Tumor differentiation
Well differentiation 1 (8.3) 5 (41.7) 6 (50) 0.804
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a The staining score of each section were calculated by staining intensity and
positive rate of cancer cells.
b clinical staging are according to UICC cancer stage.
c Chi-square test and Fisher’s exact test
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from a cellular slime mold, Dictyostelium discoideum,
localizing to crown-like structures on dorsal surface of a
various cell types [18]. Coronins comprise at least seven
members including coronin 1A, coronin 1B, coronin-1C,
coronin 2A, Coronin 2B, and Coronin 7 [19]. Coronins
play various roles in cell chemotaxis, cytokinesis, phago-
cytosis, locomotion and migration [38].
Located at cell pseudopodia and submembranous
cytoskele, Coronin 1C is ubiquitously expressed and
could be extracted from both the cytosol and the mem-
brane fraction. As F-actin bundling and crosslinking
protein [39], it is involved in F-actin-dependent pro-
cesses at cell cortex. Absence of coronin-1C inhibits
fibroblast migration as shown by Thal et al [40], who
found significantly higher levels of coronin-1C expres-
sion in glioblastoma cells than low malignancy gliomas
cells. Further, functional analyses by coronin-1C knock-
down revealed the roles of coronin-1C in regulating cell
proliferation, migration, invadopodia formation, and
invasion in glioblastoma cells [40].
The current study found that coronin-1C expression in
HCC nude mice models was correlated to the aggressive
and metastastic behaviors of HCC. We further explored
whether the detection of coronin-1C could help predict the
development of spontaneous pulmonary metastasis in nude
mice model of HCC. Coronin-1C level showed a marked
upsurge at the end of fifth wk when pulmonary metastasis
occurred, implying coronin-1C might indeed predict liver
cancer progression and lung metastasis [Fig. 4].
Based on these findings, we focused on the relation-
ship between coronin-1C and clinicopathological charac-
teristics among HCC specimens. IHC study in 115
human HCC specimens demonstrated that patients with
higher coronin-1C expression had more advanced stage,
implying that increased coronin-1C could be involved in
more aggressive growth of HCC.
In summary, the currrent work indicates the the role
of coronin-1C in HCC aggressive and metastatic beha-
vior. Coronin-1C level might reflect the pathological
progression of HCC and could be candidate biomarker
to predict HCC invasive behavior.
Conclusions
Coronin-1C could be a candidate biomarker to predict
HCC invasive behavior.
List of Abbreviations
HCC: Hepatocellular carcinoma; SDS-PAGE: Sodium
dodecyl sulfate polyacrylamide gel electrophoresis; SPF:
Specific pathogen-free; IHC: Immunohistochemistry;
ITGA3: integrin alpha 3; ECL: Enhanced chemilumines-
cence; AFP: Alpha-fetoprotein; AFPR-L3: Alpha-fetopro-
tein-L3; DCP: Des-g-carboxy-prothrombin; TGFb:
Transforming growth factor-b1; IGF-II: Insulin-like
growth factor-II; IGFBP-2: Insulin-like growth factor-
binding protein-2; HCCR: Human cervical cancer onco-
gene; GP73: Golgi protein 73; HGF: Hepatocyte growth
factor; VEGF: Vascular endothelial growth factor; TAAs:
Tumor-associated antigens;M A I D L I - T O F - M S :M a t r i x
assisted laser desorption ionization/time of flight MS; 2-
DE: Two-dimensional gel electrophoresis.
Acknowledgements
We thank Zhao Yong Ph.D. technical assistance. This work is supported by
the grants from the New-Century Excellent Talents Supporting Program of
the Ministry of Education of China (No. NCET-04-0669), the Foundation for
the Author of National Excellent Doctoral Dissertation of PR China
(No.200464), the Natural Science Foundation of China (No. 20675058), the
Science Fund for Creative Research Groups (No. 20621502, 20921062), NSFC
and Sate Key Scientific Research Project (2008ZX10002-021).
Authors’ contributions
LW carried out most parts of the experiment; C-WP, J-XH, Y-HZ, CC, and L-
DC participated in the experiment; YL conceives the study project, organizes
the whole study process, provides financial support, and finalizes the
manuscript. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 December 2009 Accepted: 24 February 2010
Published: 24 February 2010
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
2. Sell S: Mouse Models to Study the Interaction of Risk Factors for Human
Liver Cancer. Cancer Res 2003, 63:7553-7562.
3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y,
Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD: A
decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res
Clin Oncol 2004, 130:187-196.
4. El Serag HB: Hepatocellular carcinoma: recent trends in the United
States. Gastroenterology 2004, 127(5 Suppl 1):S27-S34.
5. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003,
362:1907-1917.
6. Wu L, Tang ZY, Li Y: Experimental models of hepatocellular carcinoma:
developments and evolution. J Cancer Res Clin Oncol 2009, 135:969-981.
7. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the
surveillance to molecular targeted therapy. Oncology 2008, 75(Suppl
1):1-12.
8. Llovet JM, Bruix J: Novel advancements in the management of
hepatocellular carcinoma in 2008. J Hepatol 2008, 48:S20-S37.
9. Qin LX, Tang ZY: Recent progress in predictive biomarkers for metastatic
recurrence of human hepatocellular carcinoma: a review of the
literature. J Cancer Res Clin Oncol 2004, 130:497-513.
10. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q: New human
hepatocellular carcinoma (HCC) cell line with highly metastatic potential
(MHCC97) and its expressions of the factors associated with metastasis.
Br J Cancer 1999, 81:814-821.
11. Li Y, Tang Y, Ye L, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH:
Establishment of cell clones with different metastatic potential from the
metastatic hepatocellular carcinoma cell line MHCC97. World J
Gastroenterol 2001, 7:630-636.
12. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, Xue Q: Establishment of a
hepatocellular carcinoma cell line with unique metastatic characteristics
through in vivo selection and screening for metastasis-related genes
through cDNA microarray. J Cancer Res Clin Oncol 2003, 129:43-51.
13. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY: Stepwise
metastatic human hepatocellular carcinoma cell model system with
Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:17
http://www.jeccr.com/content/29/1/17
Page 8 of 9multiple metastatic potentials established through consecutive in vivo
selection and studies on metastatic characteristics. J Cancer Res Clin
Oncol 2004, 130:460-468.
14. Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue Q, Sun RX: Serum CYFRA 21-1
level reflects hepatocellular carcinoma metastasis: study in nude mice
model and clinical patients. J Cancer Res Clin Oncol 2006, 132:515-520.
15. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, YE SL, Wu JR,
Zeng R, Wang HY, Tang ZY, Xia QC: From proteomic analysis to clinical
significance: overexpression of cytokeratin 19 correlates with
hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004, 3:73-81.
16. Albini A: Tumor microenvironment, a dangerous society leading to
cancer metastasis. From mechanisms to therapy and prevention. Cancer
Metastasis Rev 2008, 27:3-4.
17. Fackler OT, Grosse R: Cell motility through plasma membrane blebbing. J
Cell Biol 2008, 181:879-884.
18. de Hostos EL, Bradtke B, Lottspeich F, Guggenheim R, Gerisch G: Coronin,
an actin binding protein of Dictyostelium discoideum localized to cell
surface projections, has sequence similarities to G protein beta subunits.
EMBO J 1991, 10:4097-4104.
19. Uetrecht AC, Bear JE: Coronins: the return of the crown. Trends Cell Biol
2006, 16:421-426.
20. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS: Production of
embryonal alpha-globulin by transplantable mouse hepatomas.
Transplantation 1963, 1:174-180.
21. Li D, Mallory T, Satomura S: Afp-l3: a new generation of tumor marker for
hepatocellular carcinoma. Clin Chim Acta 2001, 313:15-19.
22. Weitz IC, Liebman HA: Des-gamma-carboxy (abnormal) prothrombin and
hepatocellular carcinoma: a critical review. Hepatology 1993, 18:990-997.
23. Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M: Serum
alpha-l-fucosidase: a new marker for the diagnosis of primary hepatic
carcinoma? Hepatology 1984, 4:889-892.
24. Hsu HC, Cheng W, Lai PL: Cloning and Expression of a Developmentally
Regulated Transcript MXR7 in Hepatocellular Carcinoma: Biological
Significance and Temporospatial Distribution. Cancer Res 1997,
57:5179-5184.
25. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S: Elevated levels of
transforming growth factor beta messenger RNA and its polypeptide in
human hepatocellular carcinoma. Cancer Res 1991, 51:4080-4083.
26. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D: Differential
Expression of Insulin-like Growth Factor II mRNA in Human Primary Liver
Cancers, Benign Liver Tumors, and Liver Cirrhosis. Cancer Res 1988,
48:6844-6849.
27. Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW:
Pilot study of elevated levels of insulin-like growth factor-binding
protein-2 as indicators of hepatocellular carcinoma. Horm Res 2003,
60:174-180.
28. Yoon SK, Lim NK, Ha SA, Park YG, Choi JY, Chung KW: The human cervical
cancer oncogene protein is a biomarker for human hepatocellular
carcinoma. Cancer Res 2004, 64:5434-5441.
29. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ: Gp73, a
resident golgi glycoprotein, is a novel serum marker for hepatocellular
carcinoma. J Hepatol 2005, 43:1007-1012.
30. Yamagamim H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T:
Serum concentrations of human hepatocyte growth factor is a useful
indicator for predicting the occurrence of hepatocellular carcinomas in
c-viral chronic liver diseases. Cancer 2002, 95:824-834.
31. Moriyama M, Matsumura H, Watanabe A, Nakamura H, Arakawa Y, Oshiro S:
Detection of serum and intrahepatic KL-6 in anti-HCV positive patients
with hepatocellular carcinoma. Hepatol Res 2004, 30:24-33.
32. Semela D, Dufour JF: Angiogenesis and hepatocellular carcinoma. J
Hepatol 2004, 41:864-880.
33. Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K: Preneoplastic markers of
hepatitis B virus-associated hepatocellular carcinoma. Cancer Res 2004,
64:7329-7335.
34. Hu WQ, Peng CW, Li Y: The expression and significance of P-
glycoprotein, lung resistance protein and multidrug resistance-
associated protein in gastric cancer. J Exp Clin Cancer Res 2009,
28:144-150.
35. Li W, Gomez E, Zhang Z: Immunohistochemical expression of stromal
cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in
hepatocellular carcinoma. J Exp Clin Cancer Res 2007, 26:527-533.
36. Li N, Long Y, Fan X, Liu H, Li C, Chen L, Wang Z: Proteomic analysis of
differentially expressed proteins in hepatitis B virus-related
hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009, 28:122-132.
37. Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, Huang J: Mining novel
biomarkers for prognosis of gastric cancer with serum proteomics. JE x p
Clin Cancer Res 2009, 28:126-133.
38. Rybakin V, Clemen CS: Coronin proteins as multifunctional regulators of
the cytoskeleton and membrane trafficking. Bioessays 2005, 27:625-632.
39. Spoerl Z, Stumpf M, Noegel AA, Hasse A: Oligomerization, F-actin
interaction, and membrane association of the ubiquitous mammalian
coronin 3 are mediated by its carboxyl terminus. J Biol Chem 2002,
277:48858-48867.
40. Thal D, Xavier CP, Rosentreter A, Linder S, Friedrichs B, Waha A, Pietsch T,
Stumpf M, Noegel A, Clemen C: Expression of coronin-3 (coronin-1C) in
diffuse gliomas is related to malignancy. J Pathol 2008, 214:415-424.
doi:10.1186/1756-9966-29-17
Cite this article as: Wu et al.: Coronin-1C is a novel biomarker for
hepatocellular carcinoma invasive progression identified by proteomics
analysis and clinical validation. Journal of Experimental & Clinical Cancer
Research 2010 29:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:17
http://www.jeccr.com/content/29/1/17
Page 9 of 9